NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio<
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development<
04 Jun 2026

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer,
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma<
01 Jun 2026

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Topline data from the 15-month primary endpoint expected in the second half of 2027
Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors<
26 May 2026

Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors

Adcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab
Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea<
21 May 2026

Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea

In South Korea and will benefit an estimated 34,000 new patients each year
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder<
20 May 2026

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

First time a Selective Endocannabinoid Reuptake Inhibitor (SERI) molecule is dosed in a patient population
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares<
05 May 2026

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

The shares of common stock were sold at a public offering price of $6.00 per share.
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization<
21 Apr 2026

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data
Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates<
20 Apr 2026

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Multiple clinical and regulatory updates for the Company's pipeline of first- and best-in-class ADCs.
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science<
17 Apr 2026

UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

Total transaction value of up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.